Bharat Biotech’s Covaxin has emerged as the first COVID-19 vaccine worldwide to be used for inoculating children as young as 2 years old with the subject expert committee (SEC) that counsels the Drugs Controller General of India (DCGI) endorsing emergency use authorisation (EUA) for the vaccine for kids in the 2-18 years age group.
Bharat Biotech stated that it had submitted data from clinical trials in the 2-18 years age group for Covaxin (BBV152) to CDSCO.
“The data has been comprehensively evaluated by the CDSCO and SEC have provided their positive approvals,” the company stated.
“This signifies one of the first approvals globally for COVID-19 vaccines for the 2-18 age group. Bharat Biotech genuinely express thanks to the DCGI, SEC and CDSCO for their expedited review process. We now expect further regulatory approvals from the CDSCO prior to vaccine launch and market availability of Covaxin for children,” Bharat Biotech statement added.
Source: IBEF
You may also like
-
Indian Pharma Giants Commit $19.1 Billion to US Expansion, Signalling a New Phase in Global Growth
-
Researchers Launch BHARAT Study to Build India’s First Large-Scale Ageing Biomarker Database
-
Why Indian Kitchen Spices Were Actually Ancient Preventive Medicine Systems
-
India’s Genome Is Not Western: GenomeIndia Study Calls for India-Specific Precision Medicine
-
CDSCO Tightens Drug Safety Reporting Rules, Asks Firms to File PSURs From Actual Launch Date
